
Plasmapheresis was linked to recovery in acute MOGAD attacks, but evidence was heterogeneous
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
A systematic review of 10 publications on acute MOG antibody-associated disease found that plasmapheresis was associated with favorable visual and neurologic recovery, but high heterogeneity and nonrandomized evidence prevent causal comparisons with other acute treatments.
What NurseJet pulled from the source
The review included 1,045 patients and 1,368 attacks; eight studies with 710 patients and 1,033 attacks contributed to meta-analysis. In optic neuritis, plasmapheresis was associated with improved visual acuity and an estimated 81% excellent-recovery rate, although the confidence interval was very wide. Good recovery was also common in attacks involving myelitis or cerebral disease, and pooled plasmapheresis-related adverse effects were 3%.
Why this matters for nurses
Neurology nurses help recognize evolving visual, motor, sensory, and cerebral symptoms, establish a pre-treatment baseline, and monitor patients during escalation therapy. The review supports careful response tracking while emphasizing that pooled observational recovery rates do not identify who should receive plasmapheresis or when.
Bedside takeaway
Plasmapheresis was associated with recovery in acute MOGAD, but nonrandomized evidence cannot define comparative benefit or optimal timing.
How This Applies in Practice
Use this when: Caring for a patient receiving ordered plasmapheresis for an acute MOGAD attack.
On your shift
- Document the pretreatment visual, motor, sensory, and cerebral findings available within the neurologic assessment plan.
- Use the approved apheresis monitoring pathway and trend the same clinical domains across the planned treatment course.
- Escalate neurologic deterioration, treatment intolerance, or new symptoms to the neurology and apheresis teams.
Explain this for my unit
Key takeaways
- Ten publications included 1,045 patients with 1,368 acute MOGAD attacks.
- Eight studies contributed data for meta-analysis, including 710 patients and 1,033 attacks.
- Plasmapheresis was associated with visual improvement in optic neuritis and favorable recovery in other attack presentations.
- High heterogeneity, variable timing and severity, and the absence of randomized comparisons limit treatment-effect and safety conclusions.
Practice implications
- Document the neurologic and visual baseline before treatment when feasible, follow the ordered plasmapheresis monitoring pathway, and trend the same clinical domains across exchanges. Escalate deterioration, treatment intolerance, or new symptoms promptly through the neurology and apheresis teams.
Limitations & cautions
- The evidence came from heterogeneous, nonrandomized studies with differences in attack type, severity, prior treatment, plasmapheresis timing, and outcome definitions. Recovery estimates had wide intervals, confounding by treatment selection is likely, and a low pooled adverse-effect rate cannot establish comparative safety.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
Neurology (PubMed)
Neurology (PubMed). Effectiveness and Safety of Plasmapheresis in MOGAD Attacks: A Systematic Review and Meta-Analysis.
https://pubmed.ncbi.nlm.nih.gov/42485605/
Professional education only


